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Background: Intrachromosomal amplification of chromosome 21 (iAMP21) is known to 
be associated with poor prognosis in B-cell ALL (B-ALL). To determine the frequency and 
clinical characteristics of iAMP21 in Korean B-ALL patients, we performed FISH and mul-
tiplex ligation-dependent probe amplification (MLPA) analyses. 
Methods: A total of 102 childhood B-ALL patients were screened with ETV6-RUNX1 FISH 
probes (Abbott Molecular, USA). The presence of an iAMP21 was confirmed by using 
MLPA P327 iAMP21-ERG probemix (MRC Holland, The Netherlands). 
Results: iAMP21 was detected in one of the screened B-ALL patients (1/102 patients, 
1.0%) who presented the ALL immunophenotype and complex karyotype at initial diagno-
sis. The patient relapsed twice after bone marrow transplantation. MLPA showed 12.5-Mb 
and 4.28-Mb regions of amplification and deletion, respectively. 
Conclusions: The frequency of iAMP21 is considerable in Korean pediatric patients. Our 
report suggests that iAMP21 in childhood B-ALL has very unfavorable impact on patient’s 
prognosis. Additional methods such as MLPA analysis is essential to rule out patients with 
equivocal interphase FISH results. 
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INTRODUCTION
The current treatment strategies for B-cell ALL (B-ALL) are 
based on several factors, including patient-related parameters 
as well as intrinsic characteristics of particular disease subtypes. 
Abnormalities with the most significant effects on the manage-
ment of B-ALL are t(12;21)(p13;q22)/ETV6-RUNX1 and high 
hyperdiploidy for good risk management, and t(9;22)(q34;q11)/
BCR-ABL1, t(4;11)(q21;q23)/MLL-AFF1, and near-haploidy/low 
hypodiploidy for high-risk stratiﬁcation. However, a substantial 
proportion of childhood leukemias remain genetically undefined 
or the correlation of genetic abnormalities with clinical outcome 
is not fully understood [1]. The detection of chromosomal ab-
normalities by conventional cytogenetic analysis is an essential 
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approach for the diagnosis, and its utility has been expanded by 
the development of FISH [2]. The use of FISH has enabled the 
identification of a number of alterations in patients with failed 
cytogenetic results and has led to the detection of cryptic abnor-
malities that cannot be determined [3]. 
Intrachromosomal amplification of chromosome 21 (iAMP21), 
discovered during routine screening for the presence of the 
ETV6-RUNX1 fusion by FISH analysis [3], is usually defined as 
three or more additional copies of RUNX1 signals on a single 
abnormal chromosome 21 (a total of five or more RUNX1 sig-
nals per cell) [4]. This chromosomal abnormality is found in 
1.5-2% of ALL cases [5] and is characterized by a low white 
blood cell count and a pre-B/common immunophenotype in 
children and adolescent populations [2]. A signiﬁcant ﬁnding 
was that patients with iAMP21 had an inferior outcome when 
treated with standard therapy and an improved outcome on in-
tensive therapy [6, 7]. Therefore, an accurate detection of this 
abnormality is very important for the choice of treatment. 
The morphology of the abnormal chromosome 21 is highly 
variable among cases and a variety of cytogenetic nomencla-
tures such as add(21), dup(21), and der(21) were used to de-
scribe the iAMP21 abnormalities, with the loss of chromosome 
21 and an associated gain of a marker chromosome being the 
most common [8]. Furthermore, in cases where metaphase 
chromosomes are absent, other methods should be applied to 
distinguish iAMP21 from high hyperdiploidy with extra copies of 
chromosome 21. These include a subtelomeric FISH probe for 
chromosome 21 to demonstrate that the number of RUNX1 sig-
nals is greater than the number of chromosomes 21 [4], array 
comparative genomic hybridization, single nucleotide polymor-
phism array, and multiplex ligation-dependent probe amplifica-
tion (MLPA) [9]. 
Because little data are available on the frequency and clinical 
characteristics of iAMP21 in Korean pediatric B-ALL patients, 
we comprehensively analyzed FISH data and further performed 
MLPA analysis to confirm suspected and equivocal cases. 
METHODS
1. Patient selection and FISH analysis
A total of 102 pediatric patients diagnosed with B-ALL between 
February 2009 and June 2015 were retrospectively investigated 
in this study. Of the 102 pediatric B-ALL patients, 65 were men 
(63.7%) and 37 were women (36.3%), and the median age at 
diagnosis was 5 yr (range, 0 to 19 yr) (Table 1). Written in-
formed consent was obtained from the patients or patients’ par-
ents for genetic analysis. 
The chromosomal abnormalities were comprehensively ana-
lyzed on the basis of G-banding karyotype, FISH, and multiplex 
reverse transcription-PCR (RT-PCR). The screening of iAMP21 
was performed by using FISH probe, ETV6-RUNX1 (TEL-AML1) 
dual color extra signal probe (Abbott Molecular, Abbott Park, IL, 
USA). For interphase FISH analysis, the slides were subjected 
to hybridization according to the manufacturer’s instructions. 
The slides were counterstained with 4,6-diamidino-2-phenylin-
dole. The slides were viewed at a magnification of 400×, and 
the number of interphase cells with five or more RUNX1 signals 
was counted; a total of 300 cells were counted for each sample. 
2. Detection of recurrent translocations
Total RNA was extracted from EDTA-anticoagulated blood sam-
ples by using the QIAamp RNA Blood Mini kit (Qiagen, Hilden, 
Germany). cDNA was synthesized by using the Transcriptor 
First Strand cDNA Synthesis kit (Roche Diagnostics Corp., Indi-
anapolis, IN, USA). To determine recurrent translocations, RT-
PCR was performed by using the HemaVision kit (DNA Technol-
ogy, Aarhus, Denmark) according to the manufacturer’s instruc-
Table 1. Patient characteristics 
Characteristics N %
Age at diagnosis (yr)
   <10 78 76.5 
   10-19 24 23.5 
Sex
   M 65 63.7 
   F 37 36.3 
Genetic abnormalities
   t(12;21)(p13;q22)/ETV6-RUNX1 14 13.7 
   High hyperdiploidy 10 9.8 
   t(9;22)(q34;q11)/BCR-ABL1* 7 6.9 
   MLL rearrangement† 6 5.9 
   t(1;19)(q23;p13)/TCF3-PBX1 2 2.0 
   t(16;21)(p11;q22)/FUS-ERG 2 2.0 
   Hypodiploidy 1 1.0 
   iAMP21 1 1.0 
   NOS 62 60.8 
*Five patients with e1a2, one with b2a2, and one with b3a2 fusion tran-
scripts were included; †Three patients with t(4;11)(q21;q23)/MLL-AFF1, two 
with t(11;19)(q23;p13.3)/MLL-MLLT1, and one with t(1;11)(p32;q23)/MLL-
EPS15 were included. 
Abbreviations: M, male; F, female; iAMP21, intrachromosomal amplification 
of chromosome 21; NOS, not otherwise specified. 
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tions. Recurrent genetic abnormalities were detected in 40 
(39.2%) patients, including ETV6-RUNX1 (14 patients, 13.7%), 
high hyperdiploidy (10 patients, 9.8%), BCR-ABL1 (7 patients, 
6.9%), MLL rearrangement (6 patients, 5.9%), TCF3-PBX1 (2 
patients, 2.0%), FUS-ERG (2 patients, 1.2%), and hypodiploidy 
(1 patient, 1.0%) in the order of decreasing frequency. 
3. DNA extraction and MLPA analysis
DNA was extracted from bone marrow samples of patients and 
controls by using the QIAamp DNA Blood Mini kit (Qiagen) ac-
cording to standard procedures. The presence of iAMP21 was 
retrospectively evaluated in three patients by using SALSA 
MLPA P327-B1 iAMP21-ERG probemix (MRC Holland, Amster-
dam, The Netherlands), including 46 probes encompassing a 
region around 21q11.2 to 21q22.3, according to the manufac-
turer’s instructions. Hybridized probes were amplified on a 
C1000 thermal cycler (Bio-Rad, Hercules, CA, USA). Amplicons 
were separated on an ABI 3730 capillary sequencer (Applied 
Biosystems, Foster City, CA, USA). The data were analyzed by 
using GeneMarker software (Softgenetics, State College, PA, 
USA). The relative fluorescence peak ratios were calculated 
from patients’ peak heights divided by control’s peak heights. 
Relative ratios between 0.75 and 1.3 were considered normal, 
whereas those below 0.75 and above 1.3 indicated loss or gain 
of genomic material. 
RESULTS 
1. FISH and MLPA results 
FISH screening revealed three patients with more than five 
RUNX1 signals (Fig. 1). The clinical characteristics of the three 
patients are summarized in Table 2. MLPA analysis revealed 
amplification of chromosome 21 in only patient C (Fig. 2). The 
32 probes encompassing a 12.5-Mb region around 21q21.3 to 
21q22.3, which include NCAM2, BACH1, TIAM1, OLIG2, 
KCNE2, RUNX1, SIM2, HLCS, DYRK1A, KCNJ6, ERG, ETS2, 
PSMG1, TMPRSS2, and PIPK4, showed amplification (Fig. 3). 
The average relative ratio of probes in amplified regions was 
2.82 (range, 1.87-3.50), indicating the presence of more than 
five allele copies compared with the two alleles in normal con-
Table 2. Clinical presentation at diagnosis of the three patients with RUNX1 signal increment by FISH 
Age (yr)/Sex
Initial CBC
Immunophenotype 
Genetic 
abnormalities
RUNX1 gain by 
interphase FISH 
(%)
KaryotypeWBC (×109/L)/Hb (g/dL)/
Platelet (×109/L )
A  6/M 4.48/8.7/117 CD10, CD13, CD19, CD33, CD34, CD45, 
CD79a, and TdT 
ETV6-RUNX1 17.28 46,XY[20]
B  18/F 71.23/4.1/29 CD10, CD13, CD19, CD20, CD22, CD33, 
CD38, CD45, CD79a, HLA-DR, and TdT 
ETV6-RUNX1 4.88 46,XX[17]
C  9/M 9.16/6.7/15 CD7, CD10, CD19, CD34, CD45, CD79a, 
and TdT
iAMP21* 34.8%* 44,XY,add(4)(p15.2),-5,i(7)(p10), 
-21,-22,+mar[16]/45,idem,+7[4]
*iAMP21 in patient C was detected in the second bone marrow study after 1 week of induction chemotherapy.
Abbreviations: M, male; F, female; CBC, complete blood count; WBC, white blood cell count; TdT, terminal deoxynucleotidyl transferase; iAMP21, intrachro-
mosomal amplification of chromosome 21.
Fig. 1. FISH analysis using ETV6-RUNX1 dual fusion probe revealed increments of the RUNX1 signal in three patients (A, B, and C). The 
RUNX1 signals are indicated in orange, and the ETV6 signals are indicated in green. 
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Fig. 2. Multiplex ligation-dependent probe amplification analysis of three patients (A, B, and C). The control peaks are indicated in red, and 
the patients’ peaks are indicated in blue; amplification of multiple probe sites on 21q21.1-21q22.3 was observed in patient C. 
Fig. 3. Schematic representation of regions of amplification and deletion on chromosome 21. The x-axis in the graph indicates the genomic 
position of the multiplex ligation-dependent probe amplification (MLPA) probe site mapped to the human reference genome hg19. The y-
axis indicates ratios of the patients’ fluorescence peak height relative to the controls’ peak height, as determined by MLPA analysis. Regions 
of amplification are highlighted in red and regions of deletion are highlighted in blue. 
6,000
4,000
2,000
0
6,000
4,000
2,000
0
0,000
5,000
0
A
B
C
 50 100 150 200 250 300 350 400 450 500
Position
15,000,000 20,000,000 25,000,000 30,000,000 35,000,000 40,000,000 45,000,000 50,000,000
P327_B1
3.0
2.0
1.0
0
Ra
tio
Kim J, et al.
iAMP21 in Korean childhood B-ALL
http://dx.doi.org/10.3343/alm.2016.36.5.475 www.annlabmed.org  479
trols. MIR99A on the proximal site of the amplified region and 
TFF1, ITGB2, SLC19A1, COL6A2, and PRMT2 on the distal site 
of the amplified region showed deletion signals. The average 
relative ratio of probes in the deleted regions was 0.62 (range, 
0.53-0.72).
2.  Clinical presentation and course of the patient with 
iAMP21 
A 9-yr-old boy, the patient C, was admitted because of general 
weakness for three weeks. At initial diagnosis, he showed the 
complex karyotype 44,XY,add(4)(p15.2),-5,i(7)(p10),-21, 
-22,+mar[16]/45,idem,+7[4]. At follow-up one week after the 
initiation of high-risk chemotherapy comprising the drugs vin-
cristine, prednisolone, and L-asparaginase, a bone marrow ex-
amination revealed 76.9% residual blasts in the observed mar-
row cells and the FISH analysis revealed a 34.8% RUNX1 signal 
amplification of interphase cells. Chemotherapy with vincristine 
was maintained for three years after diagnosis; however, a bone 
marrow examination showed relapse of B-ALL, and the amplifi-
cation of the RUNX1 signal was also observed. High-risk che-
motherapy with vincristine was reinitiated to treat the relapsed 
B-ALL and bone marrow transplantation from a sibling donor 
was performed after conditioning chemotherapy. The patient re-
mained in complete remission for eight months; however, a fol-
low-up bone marrow examination revealed a second relapse of 
B-ALL. After completion of the clofarabine-based reinduction 
therapy, a complete hematological remission was achieved. The 
clinical course of the patient is summarized in Fig. 4.
DISCUSSION
iAMP21 is a primary cytogenetic change, which remains con-
stant in structure between diagnosis and relapse [10]. The ALL 
patients with iAMP21 showed inferior outcomes than those from 
the other ALL subgroups, including t(9;22), low hypoploidy, and 
MLL translocation [6]. Our patient also showed an aggressive 
course, with the first relapse occurring after chemotherapy and 
the second relapse after bone marrow transplantation, suggest-
ing that one of the effects of iAMP21 is a poor prognosis. 
Previous studies reported a common region of ampliﬁcation 
spanning 6.6 Mb of chromosome 21 that almost always con-
tained RUNX1; however, other involved regions varied among 
patients [8, 11]. In addition, a 3.3-Mb deleted region in the telo-
mere was found in a large proportion of patients [10]. The am-
plified regions of our patient overlapped with the commonly re-
ported amplified regions, including RUNX1 and ERG [8]. The 
mechanism of this copy number alteration has been explained 
as chromothripsis following breakage-fusion-bridge cycles, 
which is often combined with deletions of RB1, ETV6, CDKN2A/
B, and IKZF1 [9]. 
Currently, the recommended laboratory test to detect iAMP21 
is FISH, which can also determine copy number, with probes 
Fig. 4. Clinical course of patient C. The x-axis in the graph indicates the time (months) after diagnosis. The y-axis indicates the percent of 
blast count in bone marrow (blue line) and percent recipient chimerism as measured by short tandem repeat analysis (red line). RUNX1 
signal amplification by FISH analysis was detected at 13 days after diagnosis, first relapse, and second relapse. 
100
90
80
70
60
50
40
30
20
10
0
 Diagnosis 13 days 2 9 25 38 39 40 41 44 45 46 48 51 53
Months atfer diagnosis
Clinical course
90.5
76.9
0.6 0.6 1.9 0.3 1 0.6 2.4
2.8 1.9
0.40.3 0
32
55.8
1.4
80.2
82.5
1st Relapse
2nd Relapse
Bone marrow
transplantation
Blast (%)
Chimerism (%R)
Kim J, et al.
iAMP21 in Korean childhood B-ALL
480  www.annlabmed.org http://dx.doi.org/10.3343/alm.2016.36.5.475
specific for RUNX1 [12]. However, the stratification of patients 
with interphase cells should be made with caution, because ad-
ditional RUNX1 signals are also seen in extra copies of chromo-
some 21, which are characteristic of high-hyperdiploid ALL [7]. 
The characteristic signal patterns of iAMP21 are noted as clus-
tered RUNX1 signals, with one signal, located apart, represent-
ing the normal chromosome 21 [4]. However, because con-
cerns are still present, a distinctive genomic profile of chromo-
some 21 needs to be used to confirm the accuracy of iAMP21 
diagnosis, such as by single nucleotide polymorphism array 
analysis [13] or FISH with the addition of a subtelomeric probe 
specific for chromosome 21 [11]. We suggest that MLPA is also 
helpful to verify iAMP21 in clinical settings. 
MLPA is a rapid multiplex PCR-based technique that allows 
the relative quantiﬁcation of multiple gene sites in a single test 
[14]. Although MLPA has a challenge in detection of a low per-
centage of positive cells in sample, it targets very small se-
quences and can distinguish between those differing by a single 
nucleotide. 
To our knowledge, no study has reported a case of iAMP21 in 
Korea. The prevalence of iAMP21 in childhood leukemia in our 
study (1/102 patients, 1.0%) is comparable to that of previous 
reports [5, 7, 12]. In our report, the impact of the iAMP21 on 
disease course appeared to be very unfavorable. To determine 
the exact frequency and clinical impact of iAMP21 in Korean 
patients, appropriate test strategies to detect iAMP21 are war-
ranted. To consider the prognostic implications of iAMP21 in 
patients with ALL, we suggest the inclusion of the MLPA test to 
detect iAMP21 in the initial diagnosis of ALL.  
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